Get a Quote

Ribociclib Succinate
CAS NO.: 1374639-75-4
Chemical Formula: C27H36N8O5
Molecular Weight: 552.6000
DMF&GMP status: Please contact us for details.
Description:
Ribociclib Succinate is indicated for the treatment of women with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
RIBOCICLIB SUCCINATETABLET;ORALEQ 200MG BASEKISQALINOVARTIS PHARMACEUTICALS CORP
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
832422506/17/2028DSDP
841535502/19/2031DSDP
868598005/25/2030DSDP
896263012/09/2029U-1981 U-2355 U-2356
919373211/09/2031DSDP
941613608/20/2029U-1981 U-2355 U-2356
986873911/09/2031U-1981 U-2355 U-2356
1079950604/14/2036DP
Exclusive Data
Exclusivity Code Exclusivity Expiration
I-783 07/18/2021
I-784 07/18/2021
NCE 03/13/2022